In this review:
BRUIN CLL-322: fixed-duration PVR vs. VR in R/R CLL
High-dose methotrexate & CNS relapse in ultra high-risk LBCL
LB2501 (in vivo CAR‑T) in R/R non-Hodgkin lymphoma
frontMIND: tafa-len-R-CHOP vs. R-CHOP in high-risk, aggressive B-cell lymphomas
Real-world glofitamab & epcoritamab in LBCL
GHSG HD21: PET-guided BrECADD in older patients with advanced-stage classic Hodgkin lymphoma
Gilteritinib vs. midostaurin in newly diagnosed FLT3-mutated AML
PRICELUS: CSF biomarkers for primary CNS lymphoma
OPTI-AML: 14- vs. 28-day venetoclax + azacitidine in newly diagnosed AML
KOMET-007: ziftomenib + intensive induction in newly diagnosed NPM1‑m or KMT2A-r AML
Please login below to download this issue (PDF)